Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
Haoyuan Chemexpress reported consolidated revenue of RMB2.646 billion, up 28.52%, and attributable net income of RMB308.8 million for the nine months ended September 30, 2026. Attributable net income rose 30.49%. Consolidated revenue combines multiple businesses rather than isolating CDMO service revenue. The quarterly filing is unaudited and covers the year-to-date period.
Tigermed reported consolidated revenue of RMB5.792 billion, up 15.23%, and an attributable net loss of RMB272.0 million for the nine months ended September 30, 2026. Profit excluding nonrecurring items reached RMB450.1 million, up 38.08%; investment losses weighed on reported earnings. The quarterly filing is unaudited and covers the year-to-date period.
Medicilon reported consolidated revenue of RMB1.215 billion, up 44.13%, and attributable net income of RMB92.0 million for the nine months ended September 30, 2026. The company returned to profit. Its report does not present a conventional positive-base growth rate for attributable earnings. The quarterly filing is unaudited and covers the year-to-date period.
JOINN Laboratories reported consolidated revenue of RMB1.188 billion, up 20.60%, and attributable net income of RMB929.7 million for the nine months ended September 30, 2026. Biological-asset fair-value changes contributed approximately RMB866.3 million in net gains, materially affecting reported earnings. The quarterly filing is unaudited and covers the year-to-date period.
HitGen reported consolidated revenue of RMB0.550 billion, up 48.73%, and attributable net income of RMB139.4 million for the nine months ended September 30, 2026. Attributable net income increased 50.11%. These are consolidated year-to-date figures rather than third-quarter-only results. The quarterly filing is unaudited and covers the year-to-date period.
Pharmaron reported consolidated revenue of RMB12.003 billion, up 19.01%, and attributable net income of RMB1,247.1 million for the nine months ended September 30, 2026. CDMO revenue rose 31.72%, while new CDMO orders increased more than 40%. The quarterly filing is unaudited and covers the year-to-date period.
Boji Medical reported consolidated revenue of RMB0.732 billion, up 25.24%, and attributable net income of RMB49.3 million for the nine months ended September 30, 2026. Attributable net income increased 124.95%, while net operating cash flow was negative RMB9.6 million over the period. The quarterly filing is unaudited and covers the year-to-date period.
Porton Pharma Solutions reported consolidated revenue of RMB2.765 billion, up 8.66%, and an attributable net loss of RMB112.1 million for the nine months ended September 30, 2026. The group posted an attributable loss of RMB112.1 million; impairment related to its discontinued Slovenia project affected earnings. The quarterly filing is unaudited and covers the year-to-date period.
